Skip to main content Skip to search Skip to main navigation

EMA: Update of the GACP Guideline Published

The guideline on Good Agricultural and Collection Practice (GACP) for herbal starting materials has been in place since 2006 to ensure consistent quality of herbal substances. The newly released Revision 1 updates the document to current standards, reflecting developments over the past decade such as the growing use of indoor cultivation technologies and published legal interpretations. In addition, Annex 1 introduces specific requirements for indoor cultivation practices.

Indoor cultivation facilities should contain adequate systems for air, climate and humidity control, light, water treatment, ventilation and air filtration systems. They are designed to:

  • Control access to personnel;
  • Minimise potential contamination;
  • Facilitate cleaning, maintenance and other operations;
  • Be impermeable to cleaning and disinfecting agents.

For documentation, the new Annex 1 stipulates:

  • Documentation of all relevant conditions, materials, and processes
  • Batch-specific acceptance criteria for cultivation & production
  • SOP-based document management including retention rules
  • Product specifications per batch defined and recorded
  • Cleaning activities documented in batch records/logbooks
  • Daily digital records of critical process parameters for indoor cultivation

Regarding crop maintenance and plant protection, Annex 1 stipulates:

  • Written procedures for material receipt, storage, handling, sampling, approval/rejection
  • Validation of processes, cleaning, and responsibilities documented
  • Calibration of all cultivation equipment per schedule
  • Material approval before each new cultivation cycle by QA
  • Indoor cultivation: Identify critical quality attributes (CQA) & process parameters (CPP)
  • Define in-process criteria and controls
  • Standardize cultivation process
  • Complete qualification of critical equipment and supporting systems

Source:

EMA: Good agricultural and collection practice for starting materials of herbal origin - Scientific guideline


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
What are the Basic Principles of Organisational Structures?

What are the Basic Principles of Organisational Structures?

Here's the answer:
Read more
Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

The ICH Guideline Q14 “Analytical Procedure Development” was published in November 2023. This forward-looking and regulatory-savvy document builds upon the content of ICH Q2(R2) “Validation of Analytical Procedures” and incorporates elements from ICH Q8 “Pharmaceutical Development” and ICH Q9(R1) “Quality Risk Management.”
Read more
EU: GMP Annex 19 Updated

EU: GMP Annex 19 Updated

The European Commission has published a revised version of Annex 19 “Reference and Retention Samples”. The update mainly affects requirements for reference and retention samples of parallel imported, parallel distributed and parallel traded medicinal products.
Read more
Previous
Next